Medicxi Ventures Management Jersey Ltd purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000,000 shares of the company’s stock, valued at approximately $21,800,000. NewAmsterdam Pharma comprises approximately 9.2% of Medicxi Ventures […]
NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) had its target price increased by Credit Suisse Group from $21.00 to $22.00 in a research note released on Monday, Benzinga reports. They currently have an outperform rating on the stock. NAMS has been the topic of several other reports. William Blair started coverage on NewAmsterdam Pharma in a […]